The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
Clinical trial NCT04398459 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04398459
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-01
- Primary completion
- 2024-12-31
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.